Skip to main content

BEAT HF

2627196

BEAT HF

Associated Conditions

Heart Failure

Principal Investigator

Sponsor

CVRx, Inc.

The Barostim neo - Baroreflex Activation Therapy for Heart Failure is a prospective randomized trial to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the Barostim neo system in subjects with heart failure, excluding subjects eligible for or with a Cardiac Resynchronization Therapy (CRT) device.

This study is currently enrolling.